At a glance
- What the study gets you
- Access to the study treatment being tested
- Type of study
- Interventional (receives a drug or procedure)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- ADX-626 (drug), Placebo (drug)
- How long the study runs
- Study runs about 22 months (dates as stated)
- About the drug or intervention
- ADX-626 — drug: siRNA duplex oligonucleotide · Placebo — drug: Saline
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Testing a treatment
- Ages
- 18 Years to 45 Years
- Who
- All
- Number of participants
- 44
- Started
- 2025-08-12
- Last checked
- 2026-09
Plain English Summary
What is this study?
- • Testing a new treatment for healthy adult participants
- • Phase1 - 44 participants
- • This first-in-human study will evaluate the safety and tolerability of ADX-626 in healthy participants
Who can take part?
- • Ages 18 Years to 45 Years
- • Diagnosed with healthy adult participants
Where?
- • London - Richmond Pharmacology
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
This first-in-human study will evaluate the safety and tolerability of ADX-626 in healthy participants. The study will also look at how ADX-626 interacts with the human body (the pharmacokinetics and pharmacodynamics of ADX-626).
More detail
A Phase 1, first-in-human study to assess the safety and tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ADX-626 compared with placebo in healthy participants.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years - 45 Years
- Who can join: All genders
What the study is looking for
- ✓Age 18 to 45 years at the time of agreement to take part
- ✓Males or women of non-childbearing potential (WONCBP)
- ✓Willing to comply with all study requirements while participating
- ✓Suitable venous access for blood sampling.
- ✓Body weight ≥ 50 kg and a body mass index (BMI) ≤25 kg/m2
Who cannot take part
- ✗Significant medical condition such as hypertension, diabetes, cardiovascular disease, or cancer
- ✗History of bleeding or coagulation disorders, prior instances of major bleeding, or a family history of bleeding...
- ✗Current infection
- ✗Participation in an interventional drug study within the last 90 days
See the full criteria
Where Is This Study? (1 UK site)
Richmond Pharmacology
London SE1 1YR, United Kingdom
How to Get in Touch
Nali Castillo
Sponsor contactCONTACT